邹嵩, 汪琛, 邱克勤, 田云飞, 陈仁华. 金龙胶囊在中晚期胰腺癌动脉灌注化疗中的作用[J]. 中国肿瘤临床, 2014, 41(2): 127-130. DOI: 10.3969/j.issn.1000-8179.20131319
引用本文: 邹嵩, 汪琛, 邱克勤, 田云飞, 陈仁华. 金龙胶囊在中晚期胰腺癌动脉灌注化疗中的作用[J]. 中国肿瘤临床, 2014, 41(2): 127-130. DOI: 10.3969/j.issn.1000-8179.20131319
shu
ZOU Song, WANG Chen, QIU Keqin, TIAN Yunfei, CHEN Renhua. Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(2): 127-130. DOI: 10.3969/j.issn.1000-8179.20131319
Citation: ZOU Song, WANG Chen, QIU Keqin, TIAN Yunfei, CHEN Renhua. Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(2): 127-130. DOI: 10.3969/j.issn.1000-8179.20131319
shu

金龙胶囊在中晚期胰腺癌动脉灌注化疗中的作用

Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma

    摘要
  • 摘要:
      目的   回顾性分析金龙胶囊在中晚期胰腺癌动脉灌注化疗中的作用。
      方法   将2009年1月至2013年5月中晚期胰腺癌60例患者随机分为两组：治疗组（金龙胶囊+动脉灌注化疗30例），对照组（动脉灌注化疗30例）。两组均采用健择1 000 mg/m2加入1 000 mL的生理盐水中动脉灌注。
      结果   ①治疗组CR 0例；PR 8例；SD 17例；PD 5例，总有效率（CR+PR+SD）83.33%；对照组CR 0例，PR 4例，SD 12例，PD 14例，临床有效率（CR+PR+SD）：53.33%，两组比较差异有统计学意义（P < 0.05）；②主要不良反应为消化道反应和骨髓抑制，主要为Ⅰ~Ⅱ级不良反应，Ⅲ~Ⅳ级较少，两组差异无统计学意义（P>0.05），予对症治疗后能耐受；③两者治疗前后卡氏评分比较有统计学差异（P < 0.05）；④远期疗效：治疗组1年生存率为53.3%，对照组1年生存率为33.3%，两组有统计学差异（P < 0.05）。
      结论   金龙胶囊联合动脉灌注化疗治疗胰腺癌提高了中晚期胰腺癌患者临床疗效，耐受性好，值得推广。

     

    Abstract:
      Objective   To retrospectively investigate the efficiency of Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma.
      Methods   Sixty advanced pancreatic carcinoma patients between January 2009 and May 2013 were randomly assigned into the experimental group (n=30, Jinlong capsule combined with transarterial chemoembolization) and the control group (n=30, transarterial chemoembolization). Both groups were subjected to superselective pancreas artery chemotherapy with GEMZAR at a dose of 1.0 g/m2.
      Results   The overall response rate (CR+PR) was 53.3% and the control rate was 70% (CR+PR+SD) (CR 0, PR 16, SD 5) in the experimental group, whereas those in the control group were 36.7% and 56.7% (CR 0, PR 11, SD 6), respectively. The short-term therapeutic efficacy was higher in the experimental group than in the control group (P < 0.05). No significant difference in adverse reactions, including digestive reactions and myelosuppression, almost I-II degree, was observed between the two groups (P>0.05). No significant difference in the Karnofsky performance status was observed between the two groups after the treatment (P < 0.05). The 24-month survival rate of the experimental group was 50.0%, whereas that of the control group was 33.3% (P < 0.05).
      Conclusion   The application of Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma showed good clinical effects. The patients also showed good tolerance to this treatment.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回